SCHEMBL21823796

SCHEMBL21823796

FC(F)(F)c1ccc2cc(-c3csc(-c4ncco4)n3)oc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 2/20 0.45
▸ KDM4E B2RXH2 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CDK5 Q00535 1/20 0.38
▸ CDK5R1 Q15078 1/20 0.38
▸ MAPT P10636 4/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MAPK8 P45983 1/20 0.35
▸ MAPK9 P45984 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ MPL P40238 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ GFER P55789 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ KDM4C Q9H3R0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21823768 0.82 CYP19A1 (0.44) CYP19A1KDM4EMEN1KMT2ANPSR1
SCHEMBL21823777 0.79 KDM4E (0.42) CYP19A1KDM4EMEN1KMT2ANPSR1
SCHEMBL21823951 0.71 NPC1 (0.43) KDM4EMAPTRAB9ANPC1ALDH1A1
SCHEMBL29546111 0.71 RAB9A (0.54) KDM4EMEN1KMT2AMAPTRAB9A
SCHEMBL12072711 0.70 KIF11 (0.50) CYP19A1CDK5CDK5R1RAB9ANPC1
SCHEMBL21823801 0.69 NPC1 (0.67) KDM4EMEN1KMT2AMAPTRAB9A
SCHEMBL21823815 0.68 HPGDS (0.42) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL21823771 0.68 S1PR1 (0.40) CYP19A1KDM4EMAPTRAB9ANPC1
SCHEMBL30632926 0.67 F2RL3 (0.41) GRM4
SCHEMBL29546718 0.64 KDM4C (0.36) CYP19A1KDM4EKDM4CGRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860994-B1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE UNIV BRITISH COLUMBIA (CA) 2024-08-14 — — EP disclosed
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-04-07 — — US disclosed
EP-3860994-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE The University of British Columbia (CA) 2021-08-11 — — EP disclosed
WO-2020069625-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2020-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use BRDT, CBFB, CREBBP CYP19A1 2345/4885KDM4E 2015/4885MEN1 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback